ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Graybug Vision Inc

Graybug Vision Inc (GRAY)

5.50
0.00
(0.00%)
Closed June 15 4:00PM
0.00
0.00
(0.00%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
5.50
Bid
5.26
Ask
6.55
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
5.50
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
5,685,000
Dividend Yield
-
PE Ratio
-0.81
Earnings Per Share (EPS)
-6.04
Revenue
-
Net Profit
-34.36M

About Graybug Vision Inc

Graybug Vision Inc is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company products under pipeline are; GB-501, a gene therapy delivered via a recombinant adeno-associated virus (AAV) vector... Graybug Vision Inc is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company products under pipeline are; GB-501, a gene therapy delivered via a recombinant adeno-associated virus (AAV) vector to treat corneal clouding caused by mucopolysaccharidosis type 1 (MPS1), and GB-701, a novel and potent small-molecule complement factor B inhibitor being developed to target the complement pathway as a potential treatment for geographic atrophy (GA). Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Graybug Vision Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GRAY. The last closing price for Graybug Vision was $5.50. Over the last year, Graybug Vision shares have traded in a share price range of $ 0.00 to $ 0.00.

Graybug Vision currently has 5,685,000 shares outstanding. The market capitalization of Graybug Vision is $27.74 million. Graybug Vision has a price to earnings ratio (PE ratio) of -0.81.

GRAY Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
156-71.08-92.817968137976.5898.84531778450.69676912CS
260-216.4-97.5214060388221.9530.3186540609473.35118882CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.99M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.29k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.34M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.83M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.77M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.46M

GRAY Discussion

View Posts
TruckingAngler TruckingAngler 1 year ago
Go CALC!
Maybe Iโ€™ll get my $40 pre split back!
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 1 year ago
17 shares traded today !
Go calc !
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 1 year ago
Bear-Trap???!!!. Current $2.10 with $2.31 Bid, and $7.10 ASK !
WTf
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 1 year ago
Crazy GRAY now merged to be CALC so low & projected pps $14??
Great deal or failure ?
GLTA
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 1 year ago
Will check back in seven days to see if it fell near 2.
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 1 year ago
So much for the supposed BS "vote". GRAY did whatever they wanted...

"Graybug Announces Name and Trading Symbol Change. GlobeNewswireMarch 20, 2023
REDWOOD CITY, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will become effective at 4:02 pm ET. In connection with the name change, the Company has changed its trading symbol to "CALC." The Company's common stock will commence trading on March 21, 2023 on the Nasdaq Global Market under the trading symbol "CALC." The name and trading symbol change were undertaken in connection with the previously announced merger between Graybug and CalciMedica, Inc. (CalciMedica).

About Graybug:
Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases. Founded in 2011 based on technology licensed from the Johns Hopkins University School of Medicine, Graybug has offices in Redwood City, CA, and Baltimore, MD. For more information, please visit www.graybug.vision.

About CalciMedica:
CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica's proprietary technology targets the inhibition of calcium release-activated calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results in four completed efficacy clinical trials. Auxora is in development for acute pancreatitis and asparaginase-associated pancreatitis. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com."
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 1 year ago
GRAY reverse split 1:14 on 3/20/2023...
$5.50 pre-market means .39 pre split.
Rot in hell GRAY execs....
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 1 year ago
Did GRAY r/s ???
Strange Bid/Ask???
GLTA
๐Ÿ‘๏ธ0
Eurotradr Eurotradr 2 years ago
$GRAY - Proxy Statement - Merger or Acquisition (preliminary) (prem14a) - https://ih.advfn.com/stock-market/NASDAQ/graybug-vision-GRAY/stock-news/89782121/proxy-statement-merger-or-acquisition-preliminar
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
January 11th chart opportunity
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
Overall value will 3x so seems GREAT?
๐Ÿ‘๏ธ0
Eurotradr Eurotradr 2 years ago
Because it is a reverse merger with Calcimedica, a non public company, merging into GRAY but Gray shareholders only retain 29% of the new company. Going to have to dig into this further.
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
Why is GRAY tanking on this merger news?
๐Ÿ‘๏ธ0
Eurotradr Eurotradr 2 years ago
Now we are getting somewhere!
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
GRAY merger announce so you did well!
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
11/21/202/: Graybug merger confirmed!
โ€œGraybug and CalciMedica Enter into Definitive Merger Agreement
Mentioned: GRAY
Graybug and CalciMedica Enter into Definitive Merger Agreement

-- Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica's pipeline of first-in-class product candidates for life-threatening inflammatory diseases

-- Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024

-- Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023

-- Companies will host joint webcast on November 22, 2022, at 8:00 a.m. Eastern Time

REDWOOD CITY, Calif. and LA JOLLA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) and CalciMedica Inc. (CalciMedica) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on further developing CalciMedica's lead product candidate Auxora(TM), a proprietary, intravenous-formulated, small molecule calcium-release activated calcium (CRAC) channel inhibitor, to treat life-threatening inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure (AHRF), for which there are no currently approved therapies. Auxora, which modulates the immune response and protects against tissue cell injury, has been studied in four completed efficacy clinical trials, demonstrating positive and consistent clinical results, as well as a favorable safety profile. Subject to each company's stockholder approval, the combined company is expected to trade on the Nasdaq Global Market.

With approximately $35 million in cash and cash equivalents anticipated from the combined company, including a private placement financing expected to occur immediately prior to the merger closing, the combined company is expected to have a cash runway into the second half of 2024, funding the advancement of Auxora in AP and AAP through clinical milestones in 2023. The proposed merger is expected to close in the first quarter of 2023.

"After completing a comprehensive strategic review, we determined that the proposed merger with CalciMedica would provide the best return for Graybug stockholders moving forward," said Frederic Guerard, Pharm.D., Chief Executive Officer of Graybug. "The decision by our management and board of directors to select CalciMedica to be our merger partner will allow our stockholders to participate in a company with a strong clinical-stage pipeline poised to revolutionize treatment for large, underserved patient populations suffering from life-threatening inflammatory diseases worldwide."

The combined company plans to advance the development of Auxora through multiple clinical trials and anticipates the following milestones in 2023:
-- Results from an ongoing Phase 2b clinical trial (CARPO) in AP patients with systemic inflammatory response syndrome (SIRS) in second half of 2023 -- CARPO is a randomized, double-blind, placebo-controlled, dose-ranging trial intended to establish efficacy in AP. It is expected to enroll 216 patients. AP can be a life-threatening condition where the pancreas becomes inflamed, sometimes leading to pancreatic cell death or necrosis, systemic inflammation, and organ failure. There are an estimated 275,000 hospitalizations for AP annually in the United States, of which approximately 40% present with SIRS, which can compromise the function of other tissues or organs, including the lungs, and is responsible for much of the mortality seen in AP. Details of the CARPO trial are available on clinicaltrials.gov (NCT04681066). -- Results from an ongoing investigator-sponsored Phase 1/2 clinical trial (CRSPA) in pediatric patients who develop AAP as a result of treatment with asparaginase for their underlying acute lymphoblastic leukemia (ALL) in first half of 2023 -- CRSPA is a Phase 1/2 trial being conducted in pediatric patients with AAP, which is acute pancreatitis resulting from the administration of asparaginase. Treatment with asparaginase triggers the development of AAP in 7-10% of patients with ALL, with more than half of those patients developing pancreatic necrosis. CalciMedica believes that the CRSPA trial has defined an optimal pediatric dose and plans to meet with the U.S. Food and Drug Administration in the first half of 2023 to determine the path forward for a potential accelerated approval of Auxora. Details of the CRSPA trial are available on clinicaltrials.gov (NCT04195347).

"I'm extremely pleased to announce this proposed merger with Graybug, which comes at a pivotal time for our company," said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. "This transaction will provide us with the financial strength to advance the development of our lead candidate, Auxora, in life-threatening inflammatory illnesses. We have multiple value-driving milestones expected over the next 12 months, including data from our Phase 2b CARPO clinical trial in patients with AP and a potential path to accelerated approval for Auxora in AAP. At CalciMedica, we are focused on delivering novel therapies that target CRAC channel inhibition to underserved patients with life-threatening inflammatory diseases for which no approved therapies exist. This transaction serves as a significant next step in the advancement of our important mission."

About the Proposed Transaction, Management and Organization

Graybug equity holders are expected to collectively own approximately 29% of the combined company, and pre-merger CalciMedica equity holders are expected to collectively own approximately 71% of the combined company, in each case, on a fully diluted basis using the treasury stock method. The percentage of the combined company that Graybug's equity holders will own as of the close of the transaction is subject to certain adjustments as described in the merger agreement, including an adjustment based on the amount of Graybug's net cash at closing.

Following the merger, the combined company will be headquartered in La Jolla, California and Rachel Leheny, Ph.D., will serve as Chief Executive Officer of the combined company. The merger agreement provides that the board of directors of the combined company will be composed of seven members, five selected by CalciMedica and two selected by Graybug.

The merger agreement has been unanimously approved by the boards of directors of both companies and is subject to the approvals by the stockholders of each company and other customary closing conditions.

Piper Sandler is serving as financial advisor and Fenwick & West LLP is serving as legal counsel to Graybug. Oppenheimer & Co. Inc. is serving as financial advisor and Cooley LLP is serving as legal counsel to CalciMedica.

Investor Conference Call Information

The companies will host a conference call and webcast presentation to discuss the proposed transaction as well as CalciMedica's technology and pipeline on Tuesday, November 22, 2022, at 8:00 a.m. ET. The live webcast and associated presentation can be accessed on the Investors and Media section of Graybug's website at https://investors.graybug.vision/news-events/events-presentations and CalciMedica's website at https://calcimedica.com/events, along with an archived replay following the live event. โ€œ

GLTA
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
3 months to go till January 11 chart opportunity imo
๐Ÿ‘๏ธ0
Eurotradr Eurotradr 2 years ago
Loaded up more yesterday and today at .93
Awaiting some news of acquisition or other. Tic, tic, tic...
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
GRAY on 6mo High with no news...Yet... $3+ again soon?
It was less than one year ago !
GLTA
๐Ÿ‘๏ธ0
stock1ace1 stock1ace1 2 years ago
awaiting news .. $$$$
๐Ÿ‘๏ธ0
stock1ace1 stock1ace1 2 years ago
.96 grabbed a few
๐Ÿ‘๏ธ0
stock1ace1 stock1ace1 2 years ago
Watch for news to drop $1.00 entry here

๐Ÿ‘๏ธ0
stock1ace1 stock1ace1 2 years ago
*** Pending Strategic Review/News ***

On June 28, 2022 we announced that we would conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. As part of our review, we are exploring the potential for an acquisition, company sale, merger, divestiture of assets, private placement of equity securities, or other strategic transactions. On August 11, 2022, we announced that all clinical development of GB-102, GB-401, and GB-501 had been put on hold to conserve capital pending the outcome of our strategic review.
๐Ÿ‘๏ธ0
trendzone trendzone 2 years ago
The buy out thing is gaining traction again,especially after this morning 8k,and that they plan on reducing their workforce by 70%, that could mean they are looking for a buyer or something else is up.
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
GRAY ticking UP.
May be time.
GLTA
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
Yeah, the winter in the Northern Henisphere when some results are posted by the company, when the weather turns Gray, my guess is January 9, 2023
๐Ÿ‘๏ธ0
trendzone trendzone 2 years ago
Naked shorters don't get it until it's too late,and end up burned to a crisp.
๐Ÿ‘๏ธ0
trendzone trendzone 2 years ago
Or you could see out of no where the short squeeze attackers, show up just to blow out the naked shorters.
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
Problem they may have is that any potential buyer can see their numbers and lowball them for a company purchase, .02 cents a share to avoid bankruptcy, investors or merger candidates might wait until they are up against bankruptcy next year to buy at a low price, could first see a 10:1 reverse split eventually, back to 9 or 10 a share to create a micro float of 2 million shares, many investors buy and hold micro floats for the potential of a major increase with volume so it could increase speculative investment without having to do a share registration while maintaining Nasdaq

๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
There wonโ€™t be news related to a scientific breakthrough, which if they continued their research could have occurred this winter, now investors have to hope for a merger or sale of company as best scenarios, they have enough money for 4th quarter 2023, but they donโ€™t want to file a share registration because it would halve the SP and could be delisted, major losses reported in filing, maybe they find a buyer:

โ€œFurther clinical development is on hold pending outcome of strategic review โ€” As part of Graybugโ€™s previously announced cost-containment measures, all clinical development of GB-102, GB-401, and GB-501 has been put on hold to conserve capital pending outcome of its strategic review.โ€

โ€œOn June 28, 2022 we announced that we would conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. As part of our review, we are exploring the potential for an acquisition, company sale, merger, divestiture of assets, private placement of equity securities, or other strategic transactions. On August 11, 2022, we announced that all clinical development of GB-102, GB-401, and GB-501 had been put on hold to conserve capital pending the outcome of our strategic review.

โ€œWe expect to continue to incur net losses for the foreseeable future, and, subject to our strategic review, if we continue to operate our business as we have historically, we expect our research and development expenses, general and administrative expenses, and capital expenditures to continue to increase. In particular, we expect our expenses to increase if we continue our development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products, as well as hire additional personnel, develop commercial infrastructure, pay fees to outside consultants, lawyers and accountants, and incur increased costs associated with being a public company, such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC reporting requirements, insurance and investor relations. If we continue to operate our business as we have historically our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending upon the timing of our clinical trials and our expenditures on other research and development activities. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued research and development and other current liabilities.
Recent Developments
Minimum Bid Price
On June 16, 2022, we received a written notification (the โ€œNotice Letterโ€) from Nasdaq indicating that we were not in compliance with Nasdaq Listing Rule 5450(a)(1), as the closing bid price for our common stock was below the $1.00 per share requirement for the 30 prior consecutive business days which is the minimum closing price required to maintain continued listing on the Nasdaq Stock Market under Nasdaq Listing Rule 5450(a)(1) (the โ€œMinimum Bid Requirementโ€). The Notice Letter stated that we had 180 calendar days, or until December 13, 2022, to regain compliance with the Minimum Bid Requirement.
On July 21, 2022, we received a written notification from Nasdaq indicating that we had regained compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of our common stock during the preceding ten consecutive business days, July 7, 2022 to July 20, 2022, had been at $1.00 per share or greater. Our continued compliance with the Minimum Bid Requirement is dependent on our share price and there can be no assurance that we will continue to satisfy Nasdaqโ€™s minimum financial and other requirements in future periods.โ€
๐Ÿ‘๏ธ0
Eurotradr Eurotradr 2 years ago
Small float, $55M cash, seeking merger prospects... any news and this goes parabolic IMO!!!
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
โ€œ12:39p ET 8/9/2022 - Benzinga
Graybug Vision Granted U.S. Patent Titled 'EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS (FOR RETINAL, NEURONAL OR NEURODEGENERATIVE DISEASES)'

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=11407781&OS=11407781&RS=11407781

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.โ€œ

Patents tend to be a one day rise and fall in SP, September is the month here imo
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
GRAY float so low 21m this can fly in a day as done in past. $52m in cash and value $5 pps makes it EXTREMELY under valued even after this minor pop today.
GLTA
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
GRAY on the move today 8/9 !
50x volume and +30% so far on no news!
Itโ€™s about time. This low float can EXPLODE as seen so many times beforeโ€ฆ
GLTA
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
I think it gets to 5.00 this winter with research results
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
GRAY is a current HOLD with potential $5 pps...
"SVB Securities Reaffirms Their Hold Rating on Graybug Vision (GRAY)
July 22 2022 - 05:39AM
SVB Securities analyst Marc Goodman maintained a Hold rating on Graybug Vision (GRAY โ€“ Research Report) on July 11 and set a price target of $5.00. The company's shares closed last Thursday at $1.00, close to its 52-week low of $0.72. According to TipRanks.com, Goodman is a 3-star analyst with an average return of 1.1% and a 47.8% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc. Graybug Vision has an analyst consensus of Hold, with a price target consensus of $2.50.
https://www.tipranks.com/news/blurbs/svb-securities-reaffirms-their-hold-rating-on-graybug-vision-gray?utm_source=advfn.com&utm_medium=referral . "

GLTA
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
Reviewing strategic alternatives is not a reason to buy a stock, it is not a reason for the shareprice to increase, and there was not a 53 million dollar investment.

โ€œAs of March 31, 2022, the company's cash, cash equivalents, and short-term investments totaled $55.3 million.โ€
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
6/28 - GRAY $53m investment + retaining Piper Sandler is all UP from here..

โ€œGraybug Announces Review Of Strategic Alternatives.
Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that its Board of Directors will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.

As part of this process, the Company will explore the potential for an acquisition, company sale, merger, divestiture of assets, private placement of equity securities, or other strategic transactions. As of March 31, 2022, the company's cash, cash equivalents, and short-term investments totaled $55.3 million. Graybug has retained Piper Sandler Companies to act as its financial advisor to assist with this review process.

'The goal of this strategic evaluation process is to ensure that we are exploring a range of possible options to maximize value for our shareholders while leveraging our diversified pipeline and experienced team. Pending the outcome of this review, cost-containment measures are being put in place to maximize our cash resources available,' said Frederic Guerard, PharmD, Chief Executive Officer of Graybug.โ€

GLTA
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
One more year till data is provided to public
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
.83 then run higher on news / update
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
Definitely looks like GRAY manipulation has slowed.
GRAY such low float moves FAST even on low volume...
Any further confirmations of progress & won't be able to catch the run UP...
GLTA
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
Graybug Junebug, this could be an amazing month if preliminary data is released
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
Share price holding up based on the mid-term value, and maybe surprise news along the way
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
From what I can see the first news to cause a spike wonโ€™t be till Q4 unless Iโ€™m missing something
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
That wasnโ€™t news from yesterday, I was highlighting how long people will have to wait for results (Q4 2022) for first results is another few months.
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
Great GRAY news and progress 5/27!
Volume have been ridiculously low for 6 months now so it's about time.. As seen with ASK going higher...
GLTA
๐Ÿ‘๏ธ0
StockLogistics StockLogistics 2 years ago
โ€œ"We are very excited to move GB-102 into a Phase 2 clinical trial in wet AMD in the fourth quarter of 2022, while expanding our pipeline to address additional vision-threatening retinal and corneal diseases with high unmet patient needs. We plan to use our current cash to advance GB-102, GB-401 and GB-501 to clinical readouts in 2023," said Fred Guerard, PharmD, Chief Executive Officer of Graybug.

GB-102 for wet AMD: Graybug plans to proceed with a Phase 2 clinical trial of an optimized formulation of GB-102 in wet AMD patients following successful demonstration of improved performance in an extensive battery of novel in vitro stress tests. This decision, supported by a significantly more favorable competitive landscape following recent readouts of other long-acting vascular endothelial growth factor (VEGF) inhibitors, is anticipated to result in a six-month data readout available in the third quarter of 2023. "We are confident that our optimized formulation, together with modified patient inclusion criteria, will demonstrate efficacy similar to the current standard of care while also maintaining the unprecedented duration of up to 12 months observed in the ALTISSIMO trial," said Parisa Zamiri, MD, PhD, Chief Medical Officer of Graybug.

GB-401 for POAG: In glaucoma, poor patient compliance with eye drops frequently results in suboptimal control of intraocular pressure (IOP), and degeneration of the optic nerve, leading to irreversible vision loss. GB-401 is a potentially first-in-class implant formulation containing a novel prodrug of timolol injected intravitreally with a proprietary applicator, targeting twice-yearly treatment. Initiation of a Phase 1 trial with GB-401 is planned for the first quarter of 2023, with safety and efficacy data expected to be available in the second quarter of 2023.

GB-501 for MPS1 Corneal Clouding: Graybug recently acquired RainBIO, a start-up company based in North Carolina, that developed a first-in-class gene therapy for mucopolysaccharidosis type 1 (MPS1), an inherited lysosomal storage disorder with very high prevalence of corneal clouding despite existing systemic therapies (enzyme replacement or hematopoietic stem cell transplant). GB-501 received Orphan Drug Designation from the FDA and is eligible for a Priority Review Voucher upon approval. Preclinical studies in a dog model of MPS1 demonstrated complete and sustained clearing of the cornea in all dogs, regardless of disease severity, in less than a month following a single intrastromal injection. Two-year animal data support the potential for GB-501 to cure corneal clouding and restore vision in MPS1 patients. All patients required for the Phase 1/2a trial have been identified, IND submission is expected in the second quarter of 2023, and the data readout is expected in the fourth quarter of 2023.

GB-601 for Inherited Retinal Diseases: Inherited retinal disorders such as retinitis pigmentosa, Leber's congenital amaurosis, and Stargardt's disease are the consequence of over 280 genetic mutations. To date, only one drug has been approved to address a single mutation (RPE65), which accounts for a very small fraction of IRDs, leaving the vast majority of patients without therapeutic options. Graybug recently acquired a portfolio of novel cGMP analogs, supported by a well-characterized mode of action and preclinical data in established RP disease models, from Mireca Medicines GmbH, a German preclinical start-up company. Graybug is developing these cGMP analogs as first-in-class, mutation-agnostic long-acting therapeutics to treat a majority of patients with these diseases.

GB-701 for Geographic Atrophy: Geographic atrophy (GA) represents a significant unmet medical need with over five million patients worldwide suffering from this late-stage, age-related macular degeneration for which there is currently no FDA approved treatment. Recent clinical trials have indicated that targeting the complement pathway is suitable for slowing disease progression, but these investigational therapies require up to 12 injections per year. Graybug and Insilico Medicine, a clinical-stage, end-to-end artificial intelligence (AI)-drug discovery company, recently formed a strategic partnership to leverage Insilico's AI-driven small molecule discovery platform with Graybug's unique ocular drug delivery technologies enabling Graybug to develop a sustained-release, locally administered ocular formulation of a potent factor B inhibitor as a potential treatment for this vision-threatening disease.โ€
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
GRAY 4/27/2022: Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting May 1-4, 2022.

" Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a poster presentation of preclinical data for GB-401 in primary open-angle glaucoma (POAG) at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held at the Colorado Convention Center in Denver from May 1-4, 2022.

Information is listed below and available on the ARVO website.
In Vitro and In Vivo Characterizations of GB-401, a Sustained-Release Intravitreal Implant Containing a Beta-Adrenergic Antagonist Prodrug for POAG
Presenter: Yun Yu, PhD, Associate Director R&D, Graybug Vision
Poster Session: Drug Delivery
Date and Time: Wednesday May 4, 2022; 12:30 โ€“ 2:30 PM MT (2:30 โ€“ 4:30 PM ET). Location: Poster Hall - F0151 "

GLTA
..
..
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
GRAY 3/17/2022: Cantor Fitzgerald analyst Jennifer Kim maintains Graybug Vision (NASDAQ:GRAY) lowers price target from $6 to $4.

The analyst firm set a price target for $4.00 expecting GRAY to rise to within 12 months (a possible 179.72% upside). 3 analyst firms have reported ratings in the last year.

GLTA
...
....
.....
๐Ÿ‘๏ธ0
TruckingAngler TruckingAngler 2 years ago
GRAY on the Up finally again today.
Oddly enough the algo take down seen obvious daily with pre-market + after-hours ASK always 20% more than BIDโ€ฆ

Must be decisive news on GRAYโ€™s
readouts of Phase 2b ALTISSIMO,
their lead drug candidate GB-102 has a very good chance of advancing to phase3.

GLTA
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock